ERBB2 and breast cancer: Triple negative breast cancer patients also received concomitant bevacizumab 15 mg/kg every 3 weeks; HER2-positive patients also received concomitant trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) and lapatinib (750 mg daily).